-
Frozen embryos are embryos obtained through in vitro fertilization technology. They are subjected to vitrification freezing and stored in a liquid nitrogen environment until they are ready to be used for reproduction.
Indications:
• In the process of assisted reproductive treatment, the remaining embryos after embryo transfer can be used;
• In the process of assisted reproductive treatment, fresh embryo transfer is not possible due to certain systemic factors (such as abnormal endometrium, unexplained vaginal bleeding, sudden onset of various diseases, risk of ovarian hyperstimulation syndrome, significant physical discomfort, etc.);
• For cancer patients who are not too sensitive to hormones and have sufficient time for 2-4 weeks of induction therapy.
-
Oocytes Cryopreservation is a technology that delays women's fertility. When a woman is in good health, her eggs are retrieved and subjected to vitrification freezing. They are then frozen in liquid nitrogen and can be used for reproduction when desired.
Indications:
• Cancer patients with a need for fertility preservation after evaluation before surgery, radiotherapy, or chemotherapy treatment;
• On the day of egg retrieval in IVF treatment, if the male partner is unable to provide sperm in a timely manner due to various reasons, emergency freezing or storage of remaining eggs may be necessary for the female partner;
• Delaying fertility by freezing eggs for single women is currently not in compliance with China's existing laws and regulations.
-
In-vitro maturation (IVM) of immature eggs is a technique used in IVF where immature eggs are matured in a special culture medium outside the body and can then be fertilized, developed, and implanted normally.
Indications:
• As it is usually used in conjunction with ovarian tissue cryopreservation technology, the population suitable for ovarian tissue freezing is also applicable;
• Individuals with polycystic ovarian syndrome, high risk of ovarian hyperstimulation syndrome, and poor response to gonadotropin stimulation.
-
Sperm (including spermatogonial stem cells) cryopreservation is a technology and method for men to consider future fertility planning by freezing their own sperm (including spermatogonial stem cells) in a qualified medical institution and ultimately achieving their reproductive goals through assisted reproductive technologies.
Indications:
• Adolescent and adult male cancer patients before and after treatment;
• Male cancer patients before puberty (Note: For children who cannot obtain sperm, testicular tissue or spermatogonial stem cells can be considered for cryopreservation);
• Individuals who have difficulty obtaining sperm, those who cannot obtain sperm on the day of ART due to personal factors, and those who need surgical sperm retrieval should undergo fertility preservation in advance;
• Individuals with self-immune diseases that affect male fertility, high-risk occupational groups;
• Other circumstances with demand for fertility preservation.
-
Ovarian tissue cryopreservation is a technique that involves cutting and cryopreserve a portion of ovarian tissue. It can preserve oocytes and ovarian hormone secretion function. Rapid decline in female fertility and symptoms of perimenopause may occur due to disease treatment. Freezing ovarian tissue before treatment and transplanting it back into the body after recovery can restore female fertility.
Indications:
• Patients with tumors who require immediate radiotherapy, chemotherapy, or bone marrow transplantation and do not have enough time for oocyte or embryo cryopreservation. (Note: Ovarian malignant tumors or ovarian metastases must be excluded, and patients at high risk of metastasis should consider carefully. They should also be able to tolerate laparoscopic or laparotomy ovarian biopsy surgery);
• Patients with autoimmune diseases who have failed immunotherapy (such as systemic lupus erythematosus, rheumatoid arthritis);
• Patients with hematologic disorders who require bone marrow transplantation (such as thalassemia major, aplastic anemia, sickle cell anemia);
• Patients with high-risk ovarian premature aging genes detected by family or genetic testing.
